Today: 20 July 2026
M&G plc (MNG.L) today: Barclays lifts price target to 310p — all the news on 18 November 2025
18 November 2025
2 mins read

M&G plc (MNG.L) today: Barclays lifts price target to 310p — all the news on 18 November 2025

London, 18 November 2025 — The key development for FTSE‑100 asset manager and insurer M&G plc today is a broker move from Barclays, which raised its price target to 310p (from 295p) and maintained an ‘Overweight’ rating in a sector‑wide note published this morning at 09:03. The same report also adjusted targets across UK insurance peers, underscoring a constructive stance on the group.


What changed today

  • Broker action: Barclays’ new 310p target implies upside from last night’s close and keeps M&G in its preferred list among UK life and savings groups. In the same sweep, Barclays raised targets for Legal & General and Prudential and tweaked others across the space, framing a supportive backdrop for the sector.

Shareholder register watch (latest filings)

  • Morgan Stanley stake moves: The latest TR‑1 filings show Morgan Stanley reduced its total voting interest in M&G to 5.77% (5.769458%) as of 12 November 2025 (notified 14 November), down from 6.12% (6.119767%) previously reported for 10 November. These disclosures were carried on the market’s RNS feed in recent days.

Operating momentum that’s informing the calls

  • Q3 update (5 Nov): M&G reported £1.5bn of net inflows from external clients into Asset Management in Q3 and said Asset Management AUMA stood at £335bn, with both Institutional and Wholesale franchises in net inflow.
  • Group lens: Reuters’ read‑through of the trading statement highlighted group assets under management rising to £365bn and £1.8bn of open‑business net inflows in the quarter, pointing to momentum into year‑end.

Strategy backdrop: the Dai‑ichi partnership

  • 15% strategic stake: In May, Japanese insurer Dai‑ichi Life agreed to acquire a 15% holding in M&G alongside a multi‑year distribution and product partnership expected to drive at least $6bn of flows into M&G strategies over five years and to include a Dai‑ichi board seat at M&G when the threshold is reached. The deal is intended to deepen M&G’s access to Asian clients and private‑markets opportunities.

Where the shares stand

  • Latest close before today’s note: M&G closed at 266.0p on Monday, 17 November 2025, on volume of about 6.6m shares, per exchange data.
  • Range context: As of Friday’s close, the stock was 3.8% below its 52‑week high of 279p (3 September 2025), according to MarketWatch’s running performance recap.

Other recent analyst colour

  • Berenberg upgraded M&G to ‘Buy’ in October and lifted its target to 342p, citing improving cash and capital metrics and rising dividend visibility across UK life insurers. RBC reiterated ‘Sector perform’ with a 265p target on 10 November. These calls frame today’s Barclays move within a broader sequence of constructive coverage.

What to watch next

  1. Further TR‑1 updates: Additional notifications around major holdings (up or down) have been frequent in November; any new RNS could influence sentiment.
  2. Execution on inflows: Whether Q3’s external‑client momentum persists into Q4 will be key for fee revenue trajectory.
  3. Dai‑ichi tie‑in milestones: Progress toward the full 15% stake and initial co‑manufactured products or distribution wins in Japan/Asia.

Bottom line for 18 November 2025

Today’s newsflow is led by Barclays lifting M&G’s target to 310p and reiterating ‘Overweight’, reinforcing constructive sell‑side sentiment that has built since the Q3 update and the strategic tie‑up with Dai‑ichi. With external inflows improving and the shareholder register active, investors will watch for confirmation that momentum can carry through the fourth quarter.

Disclosure: This article is for information only and does not constitute investment advice.

Marcin Frąckiewicz is the founder and CEO of TS2 Space, a satellite communications company serving customers around the world. A graduate of the Warsaw School of Economics (SGH), he has more than two decades of experience in telecommunications, satellite services and technology ventures. He writes about satellite communications, space technology, artificial intelligence and the stock market, with a particular focus on technology companies, semiconductors, emerging industries and the trends shaping global innovation. Follow Marcin Frąckiewicz on Google News, Facebook. or Linkedin.

Stock Market Today

  • Ligand Pharmaceuticals Trades Above Analysts' Target; Strong Buy Ratings Predominate
    July 20, 2026, 7:02 AM EDT. Ligand Pharmaceuticals Inc (LGN) was last changing hands at $39.60, outpacing the average 12-month analyst target price of $37.39. This consensus price forecast reflects input from 14 analysts, with projections spanning from $34.00 to $41.00 and a standard deviation of $2.558. Analyst sentiment remains notably positive, comprising 11 strong buy, 1 buy, and 3 hold recommendations, resulting in an average rating of 1.47 (with 1 as strong buy). The recent price action may prompt investors to review valuations as expectations for new targets or potential profit booking rise.
Jeff Bezos Returns to the CEO Seat: Inside Project Prometheus, the $6.2 Billion AI Manufacturing AI Startup
Previous Story

Jeff Bezos Returns to the CEO Seat: Inside Project Prometheus, the $6.2 Billion AI Manufacturing AI Startup

Google Gemini 3 Launch (19 November 2025): Features, Benchmarks, Deals and How to Use It Today
Next Story

Google Gemini 3 Launch (19 November 2025): Features, Benchmarks, Deals and How to Use It Today

Go toTop